Filing Flows › Enovis (ENOV) › Q3 2026 › vs Q2 2026
Enovis (ENOV) Q3 2026 vs Q2 2026 (quarter over quarter)
Enovis's revenue fell $24.1M (-4%) from $583M in Q2 2026 to $559M in Q3 2026. The biggest changes: Reconstructive −$21.2M (-7%); Prevention & Recovery −$2.8M (-1%). Gross margin 60.8% against 61.6% (-0.8 pts).
Enovis, Q3 2026: revenue $559M (+2% year over year), operating margin 0.6%, net earnings $3.4M, operating cash flow $71.5M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 60.8% | 61.6% | -0.8 pts |
| Operating margin | 0.6% | 3.0% | -2.4 pts |
| Net margin | 0.6% | -0.2% | +0.8 pts |
| Free cash flow margin | 6.3% | 5.3% | +0.9 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Prevention & Recovery | $285M | $288M | −$2.8M | -1% |
| Reconstructive | $273M | $295M | −$21.2M | -7% |
| Revenue | $559M | $583M | −$24.1M | -4% |
| Gross profit | $340M | $359M | −$19.4M | -5% |
| Cost of revenue | $219M | $224M | −$4.7M | -2% |
| Operating profit | $3.4M | $17.4M | −$14.0M | -81% |
| Operating expenses | $336M | $342M | −$5.4M | -2% |
| Pre-tax earnings | $1.7M | $7.5M | −$5.7M | -77% |
| Research & development | $31.3M | $31.7M | −$411K | -1% |
| SG&A | $259M | $264M | −$4.4M | -2% |
| Other operating costs | $45.8M | $46.4M | −$598K | -1% |
| Income tax benefit | $1.7M | −$8.5M | $10.2M | — |
| Net earnings | $3.4M | −$1.0M | $4.5M | — |
| Operating cash sources | $84.7M | $79.0M | $5.7M | +7% |
| Depreciation & amortization | $73.5M | $71.0M | $2.5M | +3% |
| Share-based compensation | $7.8M | $9.0M | −$1.2M | -14% |
| Working capital & other | $13.2M | $3.9M | $9.3M | +236% |
| Operating cash flow | $71.5M | $75.0M | −$3.5M | -5% |
| Free cash flow (OCF − capex) | $35.0M | $31.1M | $3.9M | +12% |
| Capital expenditures | $36.5M | $43.9M | −$7.4M | -17% |
Questions
How much did Enovis's revenue grow quarter over quarter in Q3 2026?
Enovis's revenue fell $24.1M (-4%) from $583M in Q2 2026 to $559M in Q3 2026.
What drove Enovis's revenue change in Q3 2026?
Reconstructive −$21.2M (-7%); Prevention & Recovery −$2.8M (-1%).